Sandoz Licenses Human Skin Product

5 February 1996

- Sandoz of Switzerland has licensed exclusive worldwide marketing rights to GraftSkin, a manufactured human skin product, from Organogenesis of the USA. A premarket approval application for GraftSkin in the treatment of venous stasis ulcers is currently under expedited review by the US Food and Drug Administration. Under the terms of the agreement, Sandoz will make up to $37.5 million in payments to Organogenesis in equity investments, milestone payments and research support.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight